论文部分内容阅读
的 :研究肿瘤体外药敏试验 (MTT法 )与临床用药之间的关系。方法 :将 2 10例 5种肿瘤标本 (85例卵巢癌、30例宫颈癌、2 6例胃癌、4 1例结直肠癌、2 8例乳腺癌 )的体外药敏试验 (MTT法 )结果进行分析 :比较同一药品对同一种肿瘤标本不同病例的抑制率差异 ,计算每一种肿瘤标本相对于每一种药物的抑制率的平均值 ,筛选出平均抑制率较大的药物 ,与临床上常用于该肿瘤的药物进行比较。结果 :肿瘤体外药敏存在明显个体差异 ,其抑制率差异可达 0～ 6 0 %以上 ,而其平均抑制率结果与临床用药经验比较符合 ,体外试验较敏感同时临床较常用的药物主要有卵巢癌 :用紫杉醇 (Taxol)、顺铂 (DDP)等 ;宫颈癌 :用DDP、表柔比星 (e ADM )、丝裂霉素 (MMC)等 ;胃癌 :用DDP、氟尿嘧啶 (5 FU)、博来霉素 (BLM )、MMC等 ;结直肠癌 :用DDP、MMC、BLM、5 FU等 ;乳腺癌 :用e ADM、多柔比星 (ADM )、长春瑞滨 (NVB)等。结论 :肿瘤体外药敏试验结果可以为临床个体化治疗提供参考。
: To study the relationship between in vitro drug susceptibility testing (MTT) and clinical use of drugs. Methods: In vitro susceptibility testing (MTT) was performed in 210 cases of five tumor types (85 with ovarian cancer, 30 with cervical cancer, 26 with gastric cancer, 41 with colorectal cancer, and 28 with breast cancer) Analysis: Comparison of the same drug on the same tumor specimens in different cases of inhibition rate differences in each tumor samples calculated relative to the average inhibition rate of each drug, screening out a larger average inhibition rate of drugs, and clinically used The drugs in this tumor were compared. Results: There were obvious individual differences in drug susceptibility in vitro, with the difference of up to 0 ~ 60%. The average inhibitory rate was in good agreement with clinical experience. In vitro tests were more sensitive and ovarian Cancer: Taxol, DDP and the like; Cervical cancer: DDP, e ADM, mitomycin (MMC) and the like; Gastric cancer: DDP and fluorouracil Bleomycin (BLM), MMC and the like; colorectal cancer: DDP, MMC, BLM, 5 FU and the like; breast cancer: e ADM, ADM, vinorelbine (NVB) and the like. Conclusion: The results of drug susceptibility testing in vitro can provide a reference for clinical individualized treatment.